Refer a Patient

We are starting an exciting research project at CVETS and we need your help for patient recruitment. We are investigating the effect of AlphaFlo® on osteoarthritis (OA) development in canine patients. AlphaFlo® is a commercially available canine amniotic allograft product. AlphaFlo® is comprised of cytokines, growth factors, and extracellular matrix proteins that are naturally found in amniotic tissues. Amniotic tissues possess reported anti-inflammatory, anti-microbial, anti-fibrotic, and regenerative properties. We have used AlphaFlo® at CVETS for a variety of conditions (chronic wounds, shoulder tendinopathies, iliopsoas injuries, partial CCL ruptures, others) over the last few years and have observed overwhelmingly positive results. Our goal is to observe how AlphaFlo® can mitigate the development of OA, pain management in the acute setting, and speed of healing. We are looking for 40 canine patients with acute CCL injuries to enroll in this double-blinded study. These patients will undergo the same medical process as other patients with CCL injuries, including surgical consultation and TPLO surgical procedure. After the TPLO procedure, these patients will have a stifle intra-articular injection of AlphaFlo® or sterile saline (randomly assigned during study design). These patients will be monitored every 2 weeks with goniometry, owner evaluation of pain score at home (Canine Brief Pain Inventory), gait analysis (Tekscan) and radiographs of the affected stifle. Recheck evaluations will continue every 2 weeks until 8 weeks post-operatively. The AlphaFlo® product (if randomly selected) and all recheck examinations, including radiographs will be provided free of charge to the client. Please reach out to Dr. Victoria DeMello (vdemello@cvets.net) or Dr. Erica Dunphy (edunphy@cvets.net) with any questions. Please see below for patient selection criteria: Canines evaluated and diagnosed with acute unilateral CCL injury with no obvious meniscal injury on pre-operative physical examination. The patient’s lameness must have been initially observed at least 2 weeks prior to surgery but no longer than 6 months. Patients must weigh between 15Kg- 40K Canines are to be aged between 1-7 years of age No additional selection for breed or sex of patient No co-morbidities that may affect healing including neoplasia, endocrine disorders (Cushing’s disease, Addison’s disease, Diabetes Mellitus, others). IBD, food allergies, canine atopy, etc may be considered on a case-by-case basis if well controlled.